Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET BP I: Renal Denervation for Hypertension
NCT02910414Phase 3Active, not recruiting
- Sponsor
- Ablative Solutions
- Start
- Jul 2019
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms), sponsored by Ablative Solutions. Primary endpoint: Change in mean systolic Ambulatory Blood Pressure Monitoring at 3 months. Started Jul 2019; status: active, not recruiting.
Beyond the preview
Go deeper on NCT02910414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910414.